Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Long-Term Investments (2020 - 2025)

Historic Long-Term Investments for Amphastar Pharmaceuticals (AMPH) over the last 6 years, with Q3 2025 value amounting to $13.3 million.

  • Amphastar Pharmaceuticals' Long-Term Investments rose 4148.94% to $13.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.3 million, marking a year-over-year increase of 4148.94%. This contributed to the annual value of $11.0 million for FY2024, which is 2512.09% down from last year.
  • Amphastar Pharmaceuticals' Long-Term Investments amounted to $13.3 million in Q3 2025, which was up 4148.94% from $12.1 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Long-Term Investments registered a high of $15.2 million during Q1 2024, and its lowest value of $2.0 million during Q1 2021.
  • In the last 5 years, Amphastar Pharmaceuticals' Long-Term Investments had a median value of $5.4 million in 2023 and averaged $7.3 million.
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' Long-Term Investments skyrocketed by 90000.0% in 2021, and later crashed by 3009.3% in 2025.
  • Amphastar Pharmaceuticals' Long-Term Investments (Quarter) stood at $4.0 million in 2021, then rose by 12.92% to $4.5 million in 2022, then surged by 226.33% to $14.7 million in 2023, then fell by 25.12% to $11.0 million in 2024, then increased by 20.95% to $13.3 million in 2025.
  • Its last three reported values are $13.3 million in Q3 2025, $12.1 million for Q2 2025, and $10.6 million during Q1 2025.